Kaleido Biosciences, Inc. KLDO
We take great care to ensure that the data presented and summarized in this overview for Kaleido Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KLDO
View allLatest Institutional Activity in KLDO
Top Purchases
Top Sells
About KLDO
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Transactions at KLDO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2022
|
Jerald Korn COO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,046
-31.17%
|
$2,046
$1.49 P/Share
|
|
Feb 28
2022
|
Vlieg Johan Van Hylckama Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,087
-31.12%
|
$2,087
$1.49 P/Share
|
|
Feb 08
2021
|
Daniel L Menichella Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$220,000
$11.5 P/Share
|
|
Feb 08
2021
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
215,000
+5.09%
|
$2,365,000
$11.5 P/Share
|
|
Jun 04
2020
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,000,000
+32.62%
|
$14,000,000
$7.5 P/Share
|
|
Mar 04
2019
|
Flagship Ventures Fund V General Partner LLC Director |
BUY
Open market or private purchase
|
Indirect |
933,333
+9.07%
|
$13,999,995
$15.0 P/Share
|
|
Mar 04
2019
|
Flagship Ventures Fund V General Partner LLC Director |
BUY
Conversion of derivative security
|
Indirect |
11,070,951
+30.95%
|
-
|
|
Mar 04
2019
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,120,697
+39.13%
|
-
|